Discover
LXEO
Lexeo Therapeutics, Inc.
4.45
2 x 3.39
2 x 5.59
bid
ask
-
0.21
4.40%
2 @ 05:03 AM
4.49 +0.04 (0.90%)
| Ytd | -55.19% | |
| 1y | 5.45% |
4.33
day range
4.79
3.60
52 week range
10.99
| Open | 4.67 | Prev Close | 4.66 | Low | 4.33 | High | 4.79 | Mkt Cap | 349.42M |
| Vol | 852.56K | Avg Vol | 892.75K | EPS | -1.12 | P/E | N/A | Forward P/E | -2.24 |
| Beta | N/A | Short Ratio | 6.55 | Inst. Own | 91.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 5.15 | 200-d Avg | 7.13 | 1yr Est | 22.29 |
LXEO News
seekingalpha.com
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements
benzinga.com
JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9
JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and l
benzinga.com
Lexeo Therapeutics Reports Data For LX2006 Gene Therapy In Friedreich Ataxia, Pivotal SUNRISE-FA 2 S
Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs
benzinga.com
Why Is Lexeo Therapeutics Stock Gaining Monday?
Lexeo Therapeutics stock jumps as LX2006 pivotal trial moves forward, with SUNRISE-FA 2 enrollment s
benzinga.com
Lexeo Therapeutics Finalized SUNRISE-FA Pivotal Trial Protocol And Statistical Analysis Plan Intende
SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, incl